Demcizumab, referred to as OMP 21M18 and assigned the CAS registry number 1243262-17-0, constitutes a unique monoclonal antibody designed to principally blocking certain activity of a receptor- 2. Studies suggest this https://jessegovz029955.pointblog.net/demcizumab-a-deep-investigation-into-omp-21m18-and-1243262-17-0-92586248